US2015093353A1PendingUtilityA1
Method and System for Treatment of Damaged Biological Tissue
Assignee: CORMATRIX CARDIOVASCULAR INCPriority: Jan 18, 2006Filed: Dec 10, 2014Published: Apr 2, 2015
Est. expiryJan 18, 2026(expired)· nominal 20-yr term from priority
Inventors:Robert G. Matheny
A61L 27/18A61L 27/3633A61K 31/22A61L 27/54A61K 38/1841A61K 38/39A61K 38/30A61K 38/1825A61K 38/1866A61K 31/722A61K 31/505A61K 45/06A61K 9/0019A61L 2430/20A61K 38/1741A61K 31/4418A61K 48/00A61K 31/404A61K 31/47A61L 27/3687A61K 31/40A61K 31/366A61K 38/19A61L 27/3834
52
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Biomaterial compositions comprising extracellular matrix (ECM) and an ECM-mimicking biomaterial, such as poly(glycerol sebacate) (PGS), for treating damaged biological tissue; particularly, damaged cardiovascular tissue. The biomaterial compositions can also include additional biologically active agents, such as growth factors, and polymeric materials, such as polyepsilon-caprolactone (PCL).
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A composition for treating damaged biological tissue, comprising:
a biomaterial composition comprising an extracellular matrix (ECM) material and an ECM-mimicking biomaterial, said biomaterial composition being configured to induce modulated healing when delivered to damaged biological tissue, said modulated healing comprising modulation of inflammation of said damaged tissue, and induced cell proliferation and bioremodeling of said tissue.
2 . The composition of claim 1 , wherein said ECM-mimicking biomaterial comprises poly(glycerol sebacate) (PGS).
3 . The composition of claim 1 , wherein said ECM material comprises ECM from a mammalian tissue source selected from the group consisting of small intestine submucosa (SIS), urinary bladder submucosa (UBS), stomach submucosa (SS), central nervous system tissue, mesothelial tissue, dermal extracellular matrix, subcutaneous extracellular matrix, gastrointestinal extracellular matrix, tissue surrounding growing bone, placental extracellular matrix, ornomentum extracellular matrix, cardiac extracellular matrix, kidney extracellular matrix, pancreas extracellular matrix, lung extracellular matrix, and combinations thereof.
4 . The composition of claim 1 , wherein said biomaterial composition further comprises a polymer selected from the group consisting of polyglycolide (PGA), polylactide (PLA), polyepsilon-caprolactone (PCL), poly dioxanone, poly lactide-co-glycolide, polyamide esters, polyalkalene esters, polyvinyl esters, polyvinyl alcohol, and polyanhydrides.
5 . The composition of claim 4 , wherein said polymer comprises PCL
6 . The composition of claim 1 , wherein said biomaterial composition further comprises an exogenously added biologically active agent.
7 . The composition of claim 6 , wherein said biologically active agent comprises a growth factor is selected from the group consisting of transforming growth factor alpha (TGF-α), transforming growth factor beta (TGF-β), fibroblast growth factor-2 (FGF-2), basic fibroblast growth factor (bFGF), vascular epithelial growth factor (VEGF), and insulin-like growth factor (IGF).
8 . The composition of claim 6 , wherein said biologically active agent comprises a cell selected from the group consisting of an embryonic stem cell, mesenchymal stem cell, hematopoietic stem cell, bone marrow stem cell, bone marrow-derived progenitor cell, myosatellite progenitor cell, totipotent stem cell, pluripotent stem cell, multipotent stem cells, oligopotent stem cell and unipotent stem cell.
9 . The composition of claim 6 , wherein said biologically active agent comprises a protein selected from the group consisting of collagen (types I-V), proteoglycans, glycosaminoglycans (GAGs), glycoproteins, cytokines, cell-surface associated proteins, and cell adhesion molecules (CAMs).
10 . The composition of claim 6 , wherein said biologically active agent comprises statin selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin.
11 . The composition of claim 1 , wherein said biomaterial composition further comprises a pharmacological agent.
12 . The composition of claim 11 , wherein said pharmacological agent comprises an agent selected from the group consisting of an anti-viral agent, analgesic, antibiotic, anti-inflammatory, anti-neoplastic, anti-spasmodic, enzyme and enzyme inhibitor, anticoagulant and/or antithrombic agent, and vasodilating agent.Join the waitlist — get patent alerts
Track US2015093353A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.